Editing Page Tests

Submitted by Anonymous on Jun 27, 2022

Lorem ipsum dolor sit amet

Consectetur adipiscing elit.

Donec non gravida elit, quis sollicitudin eros. Nulla imperdiet eros vel euismod egestas. Morbi semper euismod nisl quis commodo. Quisque egestas purus massa, in porttitor erat tempor in. Pellentesque scelerisque metus vel nisl maximus, in ullamcorper leo cursus. Phasellus suscipit odio sit amet fringilla vestibulum. Morbi malesuada, justo vitae rhoncus pharetra, felis nunc euismod ante, vitae posuere magna elit et leo. Sed dapibus enim nunc, vitae bibendum diam volutpat.

Quisque viverra augue quis aliquet tincidunt.

Nam eget bibendum purus. Aenean in pretium velit. Etiam tincidunt magna ac justo cursus eleifend sed non risus. Fusce tempor diam mauris, in vestibulum nisl consequat a. Proin venenatis mauris id est tincidunt mattis. Nunc fringilla aliquet velit, ac interdum eros tincidunt in. Proin ut est gravida, congue purus sit amet, tristique neque. Suspendisse vitae ligula mauris. Cras porta vestibulum tellus sit amet eleifend. In finibus bibendum arcu ut rutrum.

 

Diseasesort descending Investigator Location Phase Trial Status Detail
Amyotrophic Lateral Sclerosis (ALS)
Namita Goyal, M.D.
 UCI
  • Phase 3
 Closed UCI's Trial in Neurological Diseases ( A Phase 3, Randomized Double-Blind, Placebo-Controlled Multicenter Study to Evaluate Efficacy and Safety of Repeated Administration of NurOwn® (Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors) in Participants With ALS )
Beta-Thalassemia
Gary Schiller, M.D.
 UCLA
  • Phase 1/2
 Active, Not Recruiting UCLA's Trial in Blood Diseases ( A Phase 1/2, Open-label, Single-arm Study to Assess the Safety, Tolerability, and Efficacy of ST-400 Autologous Hematopoietic Stem Cell Transplant for Treatment of Transfusion-Dependent Beta-thalassemia (TDT) )
Critical Limb Ischemia
Isabella Jade Kuo, M.D.
 UCI
  • Phase 3
 Active, Not Recruiting UCI's Trial in Blood Diseases ( Efficacy, Tolerability and Safety of Intramuscular Injections of PLX PAD for the Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization )
End-Stage Renal Disease
Roy Fujitani, M.D.
 UCI
  • Phase 3
 Recruiting UCI's Trial in Kidney Diseases ( A Phase 3 Study to Compare the Efficacy and Safety of Humacytes Human Acellular Vessel with that of an Autologous Arteriovenous Fistula in Subjects with End-Stage Renal Disease )
Glioblastoma
Daniela Bota, M.D., Ph.D.
 UCI
  • Phase 2
 Active, Not Recruiting UCI's Trial in Cancer Diseases ( Phase II Trial of Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens (AV-GBM-1) as an Adjunctive Therapy Following Primary Surgery Plus Concurrent Chemoradiation in Patients With Newly Diagnosed Glioblastoma )
HIV
Ronald Mitsuyasu, M.D.
 UCLA
  • Phase 1/2
 Closed UCLA's Trial in HIV/AIDS Diseases ( Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection )
HIV
Ronald Mitsuyasu, M.D.
 UCLA
  • Phase 1
 Recruiting UCLA's Trial in HIV/AIDS Diseases ( A Pilot Study to Evaluate the Feasibility, Safety and Engraftment of Zinc Finger Nuclease (ZFN) CCR5 Modified CD34+ Hematopoietic Stem/Progenitor Cells (SB-728mR-HSPC) in HIV-1 (R5) Infected Patients )
Ischemic Stroke
Leonid Groysman, M.D.
 UCI
  • Phase 2
 Closed UCI's Trial in Neurological Diseases ( A Randomized, Placebo-Controlled Study of the Efficacy and Safety of Intracerebral Stem Cells (CTX0E03) in Subjects With Disability Following an Ischemic Stroke )
Limbal Stem Cell Deficiency
Sophie Deng, MD, PhD
 UCLA
  • Phase 1
 Recruiting UCLA's Trial in Eye Diseases ( Stem Cell Therapy for Limbal Stem Cell Deficiency )
Limbal Stem-cell Deficiency UCLA
  • Phase 1
 Recruiting UCLA's Trial in Eye Diseases ( Safety and Feasibility of Cultivated Autologous Limbal Stem Cells (cLSC) for Limbal Stem Cell Deficiency )
Lung Cancer
Steven M. Dubinett, M.D.
 UCLA
  • Phase 1
 Recruiting UCLA's Trial in Cancer Diseases ( A Phase I Trial of Intratumoral Administration of CCL21-gene Modified Dendritic Cell (DC) Combined With Intravenous Pembrolizumab for Advanced NSCLC )
Multiple Myeloma
Sarah Larson, M.D.
 UCLA
  • Phase 1
 Closed UCLA's Trial in Cancer Diseases ( Adoptive Transfer of NY-ESO-1 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) and Peripheral Blood Stem Cells (PBSC) After a High Dose Melphalan Conditioning Regimen, With Administration of Interleukin-2, in Patients With Multiple Myeloma )
Non-small cell lung cancer
Edward B Garon, MD, MS
 UCLA
  • Phase 1
 Recruiting UCLA's Trial in Cancer Diseases ( CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer )
Sarcoma
Theodore Nowicki, MD
 UCLA
  • Phase 1
 Recruiting UCLA's Trial in Cancer Diseases ( Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer (NYESO SCT) )
Sarcoma/Solid Tumors
Theodore Scott Nowicki, M.D., Ph.D.;
 UCLA
  • Phase 1
 Recruiting UCLA's Trial in Cancer Diseases ( Adoptive Transfer of NY-ESO-1 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) and Peripheral Blood Stem Cells (PBSC) After a Myeloablative Conditioning Regimen, With Administration of Interleukin-2, in Patients With Advanced Malignancies )
Severe Combined Immunodeficiency Due to Adenosine Deaminase Deficiency UCLA
  • Phase 1/2
 Closed UCLA's Trial in Blood Diseases ( Autologous Transplantation of Bone Marrow CD34+ Stem/Progenitor Cells After Addition of a Normal Human ADA cDNA by the EFS-ADA Lentiviral Vector for Adenosine Deaminase (ADA)-Deficient Severe Combined Immunodeficiency (SCID) )
Severe Combined Immunodeficiency Due to Adenosine Deaminase Deficiency (Cryopreserved) UCLA
  • Phase 1/2
 Closed UCLA's Trial in Blood Diseases ( Efficacy and Safety of Cryopreserved Formulation of Autologous CD34+ Hematopoietic Stem Cells Transduced Ex Vivo With EFS Lentiviral Vector Encoding for Human ADA Gene in Subjects With Severe Combined Immunodeficiency Due to ADA Deficiency )
Sickle Cell Disease UCLA
  • Phase 1/2
 Recruiting UCLA's Trial in Blood Diseases ( Stem Cell Gene Therapy for Sickle Cell Disease )
Sickle Cell Disease
Mark Walters, MD
 UCLA
  • Phase 1/2
 Not Yet Recruiting UCLA's Trial in Blood Diseases ( Transplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease )
Sickle Cell Disease
Gary Schiller, M.D.;
 UCLA
  • Phase 1
 Recruiting UCLA's Trial in Diseases ( Clinical Research Study of Autologous Stem Cell Transplantation for Sickle Cell Disease (SCD) Using Peripheral Blood CD34+ Cells Modified With the Lenti/G-βAS3-FB Lentiviral Vector )